In conclusion, a number of factors should be taken into consideration before establishing a connection between CAP, platelet activation, and MI. Platelets' pathophysiological interplay between inflammation and thrombosis suggested by in vitro studies needs to be further investigated in well-designed clinical studies with robust platelet activation markers.
activation prior to CAP should be considered as a significant limitation of the study that possibly confounds its results.
In addition, the editorial by Santos-Gallego and Badimon (2) raises an important question regarding the role of platelet aggregation as a risk factor or a risk marker in these entities. However, platelet aggregation was not assessed in the present study, In this population-based cohort study, Cangemi et al.
(1) found that increased platelet activation and thromboxane overproduction was associated with myocardial infarction in patients with pneumonia.
Moreover, they also suggested that aspirin alone was insufficient to inhibit thromboxane production.
Although, the study is observational in nature, it adds to already accumulated evidence that suggests Hence, statins may be tested as an alternative to aspirin or on top of aspirin to assess whether they are able to reduce cardiac complications in patients with CAP. 
